Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

Leukemia

Volumn 30, Issue 1, 2016, Pages 136-143

  Jawhar, M ^a   Schwaab, J ^a   Schnittger, S ^b   Meggendorfer, M ^b   Pfirrmann, M ^c   Sotlar, K ^c   Horny, H P ^c   Metzgeroth, G ^a   Kluger, S ^a   Naumann, N ^a   Haferlach, C ^b   Haferlach, T ^b   Valent, P ^d   Hofmann, W K ^a   Fabarius, A ^a   Cross, N C P ^e,f   Reiter, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASXL1 PROTEIN; BETA3 INTEGRIN; CD14 ANTIGEN; CD34 ANTIGEN; HEMOGLOBIN; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; K RAS PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE KIT; SRSF2 PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; TRYPTASE; UNCLASSIFIED DRUG; UVOMORULIN; ASXL1 PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; RIBONUCLEOPROTEIN; RUNX1 PROTEIN, HUMAN; SRSF2 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC IDENTIFICATION; GENOTYPE; HEPATOMEGALY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC MASTOCYTOSIS; BLOOD; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HUMANS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; REPRESSOR PROTEINS; RIBONUCLEOPROTEINS; RISK;

EID: 84953368012     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.284     Document Type: Article

References (35)

1. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625.
3. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013; 88: 612-624.
4. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med 2015; 373: 163-172.
5. Pardanani A. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 2015; 90: 250-262.
6. Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81-88.
7. Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011; 13: 180-188.
8. Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bultmann B et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010; 220: 586-595.
9. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460-2466.
10. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Nextgeneration sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858-3865.
11. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
12. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080-3088.
13. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123: 2220-2228.
14. Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia 2015; 29: 1115-1122.
15. Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28: 1804-1810.
16. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
17. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428-2436.
18. Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J 2015; 5: e280.
19. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; 28: 1494-1500.
20. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, Paschka P et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011; 29: 1364-1372.
21. Horny HP, Akin, Metcalfe DD, Swerdlow SH, Campo E, Harris NL et al. World Health Organization (WHO) Classification of Tumours. Mastocytosis (Mast cell disease). Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008; vol. 2, 54-63.
22. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115: 3842-3847.
23. Hanssens K, Brenet F, Agopian J, Georgin-Lavialle S, Damaj G, Cabaret L et al. SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica 2014; 99: 830-835.
24. Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014; 9: e85362.
25. Traina F, Visconte V, Jankowska AM, Makishima H, O'Keefe CL, Elson P et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 2012; 7: e43090.
26. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900-904.
27. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
28. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012; 120: 4168-4171.
29. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
30. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011; 117: 2348-2357.
31. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van't Wout JW, Verhoef G, Gerrits WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-4276.
32. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al. Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial. Blood 2014; 124: 21.
33. Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264-3274.
34. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 2015; 100: 479-488.
35. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 2015; 126: 790-797.